Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis

Yong-ho Lee; Yongin Cho; Byung-Wan Lee; Cheol-Young Park; Dae Ho Lee; Bong-Soo Cha; Eun-Jung Rhee

doi:10.4093/dmj.2019.0011

Journal List > Diabetes Metab J > v.43(1) > 1142355

Go to TopGo to Top Go to BottomGo to Bottom

This article has been corrected. See "Corrigenda: Table Correction. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis" in Volume 43 on page 731.

TOOLS

Lee, Cho, Lee, Park, Lee, Cha, and Rhee: Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis

Review

Complications

Diabetes & Metabolism Journal 2019; 43(1): 31-45.

Published online: 17 December 2018

DOI: https://doi.org/10.4093/dmj.2019.0011

Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis

Yong-ho Lee^1,², Yongin Cho^1,², Byung-Wan Lee^1,², Cheol-Young Park³, Dae Ho Lee⁴, Bong-Soo Cha^1,², Eun-Jung Rhee³

¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

²Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.

³Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

⁴Department of Internal Medicine, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea.

Corresponding author: Eun-Jung Rhee. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea. ejrhee.lee@samsung.com

Received 14 January 2019 Accepted 1 February 2019

Korean Diabetes Association

(open-access, http://creativecommons.org/licenses/by-nc/4.0/):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general population (around 25%), 50% to 70% of people with diabetes have NAFLD, and NAFLD severity (including fibrosis) tends to be worsened by the presence of diabetes. NAFLD is considered an emerging risk factor for type 2 diabetes mellitus and a contributor to the development of chronic diabetes-related complications. This reciprocal relationship demonstrates the importance of confirming suspected NAFLD in patients with diabetes. Due to the invasive nature of liver biopsy to assess NAFLD status, various alternative non-invasive modalities have been developed and validated. Here, we summarized the epidemiology of NAFLD in patients with diabetes and reviewed currently available imaging modalities and biomarker-based prediction models for their ability to detect liver steatosis and/or fibrosis.

Keywords: Diabetes mellitus, Diagnosis, Epidemiology, Non-alcoholic fatty liver disease

INTRODUCTION

The prevalence of diabetes is rising. According to Diabetes Atlas 2017, 425 million people suffer from diabetes worldwide; the prevalence rate in Korea is 14.4% according to the Diabetes Fact Sheet 2018 [1 2]. Type 2 diabetes mellitus (T2DM) is caused by derangements in multiple organs and by various pathophysiological abnormalities, such that it is implicated in many other diseases related to insulin resistance and obesity, such as nonalcoholic fatty liver disease (NAFLD), sleep apnea, arthritis, cardiovascular disease (CVD), and metabolic syndrome (MetS) [3 4].

NAFLD is considered the hepatic manifestation of ectopic fat accumulation caused by abdominal obesity and insulin resistance; its presence also reflects visceral, intramuscular, epicardial, and perivascular fat accumulation. Recent evidence suggests that NAFLD should be considered a cardiovascular risk factor [4]. NAFLD is a strong clinical signal for insulin resistance and MetS, and is considered a confirmative risk factor for T2DM [2]. Prevalence of NAFLD in patients with T2DM is much higher than in the general population. This review summarizes the epidemiology of NAFLD relative to T2DM, and compares various approaches to diagnose and assess NAFLD characteristics, including steatohepatitis and fibrosis.

PREVALENCE OF NAFLD IN THE GENERAL POPULATION

The current prevalence of NAFLD is proportional to increased rates of obesity. NAFLD incidence in the general population is about 25%, but it rises to more than 90% for very obese individuals undergoing weight reduction procedures/surgeries [5]. In addition, like obesity, NAFLD displays different characteristics among various ethnic groups and across countries [6].

In the general Korean population, some discrepancies exist in NAFLD prevalence. In a study by Park et al. [7] in which 4,967 young, healthy Koreans participated in a health screening program, the age-adjusted NAFLD prevalence rate was 21.6% (men), 11.2% (women), and 16.1% in the whole population. According to Jeong et al. [8], in a cross-sectional study of 140,000 participants in a health screening program, the NAFLD prevalence rate was 25.2%, with some differences based on where participants lived.

PREVALENCE OF NAFLD IN PATIENTS WITH T2DM

NAFLD prevalence in patients with T2DM is much higher than in the general population. In a systemic review by Lonardo et al. [9], the NAFLD incidence rate in patients with T2DM is 50% to 75%, according to ethnicity, across studies. In reverse, the prevalence of diabetes in patients with NAFLD is higher than in the general population. In a study by Browning et al. [10] of 2,287 urban people participating in the Dallas Heart Study, hepatic triglyceride content was measured by 1H-nuclear magnetic resonance spectroscopy (MRS), with prevalence of T2DM or impaired fasting glucose (IFG) reported as 18% to 33% in patients with NAFLD.

There is discrepancy between the studies regarding prevalence of NAFLD in patients with T2DM, which may be accounted for by the diagnostic tools used [11]. The prevalence of NAFLD was 20.3% when plasma alanine aminotransferase was used to define NAFLD, whereas the prevalence reached 72.8% when MRS was used to define NAFLD. In addition, NAFLD prevalence in patients with T2DM significantly increased with increasing obesity [11].

NAFLD prevalence in Asians is never lower than in Caucasians. In 929 Korean patients with T2DM who visited a university-based diabetes clinic, NAFLD was assessed by ultrasonogram [12], and 63.3% of patients had NAFLD. In 8,352 Japanese patients who received health check-ups from 2009 to 2010, NAFLD incidence was 25.6% in those with normal fasting glucose, 56.2% in those with IFG, and 68% in those with T2DM defined as fasting blood glucose ≥126 mg/dL, suggesting NAFLD prevalence could differ by glycemic status [13].

NAFLD AS A RISK FACTOR FOR T2DM

There is convincing evidence that NAFLD often precedes the development of T2DM [14]. Some suggest that the conventional paradigm of NAFLD to represent ‘hepatic manifestation’ of MetS is outdated, as recently NALFD has been shown to be an early predictor and determinant for development of diabetes.

By examining the pathophysiological aspects of insulin resistance in NAFLD development, we can understand the intimate relationship between these conditions. NAFLD is associated with hepatic and peripheral insulin resistance, causing insufficient suppression of hepatic gluconeogenesis, decreased glycogen synthesis, and increased lipid accumulation [3]. The influx of high amounts of free fatty acid (FFA) from white adipose and dietary lipids into the liver promotes further glucose synthesis. De novo synthesis of FFA is driven by sterol regulatory element binding-protein 1c (Srebp-1c) and carbohydrate response element binding-protein (ChREBP), catalyzed by hyperinsulinemia and hyperglycemia. Further factors such as decreased lipid export through very-low density lipoprotein, increased hepatic insulin resistance via diacylglycerol, and increased oxidative stress mediated due to exhaustion of antioxidant capacities of superoxide dismutase and glutamate peroxidase, ultimately result in development of NAFLD and progression to nonalcoholic steatohepatitis (NASH) in insulin resistant patients.

Meta-analyses have shown a 1.6- to 6.8-fold increased risk for diabetes in subjects with NAFLD according to established diagnostic methods, definitions, and the risk factors included for adjustment in the model [4 15]. In 5,372 non-diabetic Koreans in whom health screening was performed repeatedly in 5 years; interval, after adjustment for confounding factors, relative risk for T2DM was 1.97 in all participants and 2.29 after excluding frequent drinkers [16]. In another study analyzed in nondiabetic 11,091 Koreans in whom health screening was performed repeatedly in 5 years; interval, the odds ratio for T2DM was 2.05 after adjustment for confounding factors, and this risk was highest in those with the highest baseline insulin levels [17].

Although NAFLD is a definite risk factor for T2DM, risk could be attenuated if NAFLD is resolved. In 13,218 nondiabetic Korean participants in a health promotion center, incident diabetes was assessed at 5 years [18] by dividing them into six groups according to hepatic steatosis status at baseline and 5 years later. Using “no steatosis at baseline or follow-up” as the reference group, steatosis at baseline and follow-up showed a 2.78-fold increased risk for T2DM, and worsening severity of steatosis at follow-up showed a 7.38-fold increased risk. However, steatosis at baseline but not at follow-up showed no increased risk for T2DM compared to the reference group, suggesting that resolution of steatosis attenuated T2DM risk. Similar results were observed in another study of 4,604 Japanese participants at 10 years of follow-up [19]. In a study by Bae et al. [20], NAFLD status was assessed in 7,849 non-diabetic subjects over 5 years. Those with NAFLD for 5 consecutive years showed a 1.55-fold increased risk for T2DM compared with those who never had NAFLD, and participants with intermittent NAFLD showed no increased risk for T2DM, suggesting that persistent NAFLD presence affects risk for T2DM more strongly.

While it is evident that NAFLD is a significant risk factor for T2DM, certain conditions promote that risk. In a retrospective study of 12,853 non-diabetic Korean participants, those with any of insulin resistance, overweight/obesity, and steatosis independently doubled the risk of T2DM [21]. However, when these three conditions co-occurred, risk increased 14-fold, suggesting their combined influence on T2DM risk. In a study by Bae et al. [22], participants with IFG and NAFLD showed a 9-fold increased risk for T2DM at 5 years compared with the group without IFG and NAFLD. In addition, there was an additive effect of NAFLD on development of T2DM in individuals with MetS, and the risk for T2DM increased when elevated liver enzymes or increased fibrosis scores were accompanied by NAFLD [23 24 25].

It is apparent that NAFLD is an established risk factor for T2DM. Further, NAFLD resolution attenuates T2DM risk, but when obesity, insulin resistance, or hyperglycemia is combined with NAFLD, T2DM risk significantly increases.

T2DM AS A RISK FACTOR FOR NASH AND FIBROSIS

While presence of NAFLD may not predict any clinical abnormalities other than T2DM, progression of NAFLD to NASH or fibrosis, and further development of cirrhosis, is a serious problem. A 10% to 35% of those with normal liver histology progresses to steatosis and 12% to 40% of those with hepatic steatosis progress to steatohepatitis, and up to 15% of patients with NASH are known to progress to cirrhosis [26].

The factors that affect progression of NAFLD to NASH are unknown. One study reports on 129 biopsy-proven subjects with NAFLD that were followed for 13.7 years [27]. Although baseline glycemic status was unknown, 78% of participants at follow-up had diabetes, and insulin resistance was more prominent in those with progressive versus nonprogressive fibrosis, suggesting dysglycemia as a factor for progression to fibrosis. In 1,918 Hong Kong patients with diabetes in whom fibroscan was performed, 17.7% showed significant liver stiffness [28]. In a Rotterdam study of 3,041 participants, those with baseline diabetes and NAFLD showed a significantly higher probability of liver stiffness compared as those without diabetes or NAFLD, and age, diabetes and NAFLD were the factors that aggravated liver stiffness [28 29]. In 108 patients who had two liver biopsies in a median interval of 6.6 years, there was a significantly higher proportion of patients with T2DM among those who progressed to fibrosis compared with those who did not [30]. In one study of biopsy-proven NAFLD patients, the proportion of those with diabetes significantly increased as fibrosis stage worsened from 0 to 4 [31]; and in another study, diabetes was the significant predictor for fibrosis in patients with biopsy-proven NAFLD [32].

Based on these results, Tilg et al. [3] recently suggested a clinical algorithm to screen and manage NAFLD by which patients with NAFLD should be screened for MetS and T2DM and, as patients with T2DM are at very high risk for NAFLD, screening for NAFLD should be performed irrespective of serum liver enzyme levels and elastography should be considered in these patients to detect liver stiffness.

NAFLD AS AN AGGRAVATING FACTOR FOR DIABETIC COMPLICATIONS

There is evidence that presence of NAFLD in patients with T2DM aggravates diabetic complications [33]. In 2,839 T2DM patients, those with NAFLD showed a significantly higher prevalence of CVD [34]. The risk for macrovascular complications remained significantly increased after adjustment for multiple risk factors. In 2,103 patients with T2DM and NAFLD ascertained by history and ultrasonogram, the risk for proliferative retinopathy and chronic kidney disease, respectively, were 1.75- and 1.87-fold increased compared with those who did not have NAFLD, suggesting risk for microvascular as well as macrovascular complications is significantly associated with NAFLD in T2DM [35].

Other study results suggest increased mortality in patients with T2DM and NAFLD. In 337 patients with diabetes followed for 10.9 years, more liver-related deaths occurred in those with versus without NAFLD [36]. In addition, in a multivariate model, NAFLD significantly predicted death in patients with T2DM after adjustment for confounding factors.

Increased risk for diabetic complications in the presence of NAFLD was similarly observed in patients with type 1 diabetes mellitus (T1DM). In 250 T1DM patients, NAFLD prevalence was 44.4%, and the prevalence of CVD and microvascular disease was significantly higher in those with versus without NAFLD [37 38]. These results suggest a deleterious effect of NAFLD on vasculature, which is commonly seen in patients with T1DM and T2DM.

DIAGNOSIS OF NAFLD

In individuals with and without diabetes, a two-step process should be used to diagnose NAFLD: (1) existence of hepatic steatosis, either by imaging or histology; and (2) exclusion of secondary causes of liver steatosis as described in Table 1 [39 40]. Other endocrinologic disorders such as hypothyroidism, hypopituitarism, and hypogonadism are also associated with NAFLD; therefore, related laboratory assessments should be considered for patients with signs or symptoms of these endocrinopathies.

NAFLD spans the spectrum of fatty liver conditions, from simple steatosis (nonalcoholic fatty liver [NAFL]) and steatohepatitis (NASH) to advanced fibrosis or cirrhosis. By histologic liver biopsy, NAFL is defined as ≥5% hepatic steatosis with no evidence of hepatocellular injury (hepatocyte ballooning). NASH is a combination of NAFL and inflammation with hepatocyte injury (e.g., ballooning), with or without fibrosis.

IMAGING MODALITIES TO ASSESS HEPATIC STEATOSIS

Despite its invasive nature and sampling variability [41], liver biopsy remains the gold standard to assess hepatic steatosis, inflammation, and fibrosis in patients with NAFLD. It should be considered for patients suspected to have advanced fibrosis or when exclusion of other chronic liver diseases is needed. To overcome its high costs and risks, alternative noninvasive imaging, clinical, and laboratory modalities have been developed and validated to diagnose NAFLD.

Currently, ultrasonography (US), computed tomography (CT), magnetic resonance imaging (MRI), MRS, and transient elastography (TE) are widely available tools to measure hepatic steatosis (Table 2) [42 43 44 45 46 47 48 49 50 51].

Ultrasonography

US is the recommended first line screening method for patients with T2DM by the European NAFLD guidelines [42]. Although US has interobserver variability and limited sensitivity to detect mild (<20%) steatosis [52] or morbid obesity (body mass index [BMI] >40 kg/m²) [53], it can provide additional information about liver structure. In a meta-analysis, US achieved pooled sensitivity of 84.8% and pooled specificity of 93.6% to detect ≥20% to 30% steatosis, compared with histology [52]. However, US is limited in accuracy and reproducibility as echogenicity, an essential sonographic feature to assess degree of fat content, can be affected by various patient (obesity, coexistent kidney disease) and acquisition (device, operator, instrument settings) factors.

Computed tomography

CT scanners are standardized to obtain pixel value measurements relative to water using a dimensionless unit known as the Hounsfield unit (HU). Radiodensity of water is 0 HU by definition and air is defined as −1,000 HU [54]. In non-contrast CT, normal liver parenchyma and fat are about 50 to 60 and −20 to −100 HU, respectively. Due to inconsistency in HU calibration by external factors, ‘fat-free spleen’ can be used as an internal reference [55]. Although various criteria to define steatosis have been proposed, hepatic HU less than 40 or (liver HU-spleen HU) less than −10 can detect steatosis [43] with sensitivity and specificity ranging from 46% to 72% and 88% to 95%, respectively [56]. Similar to US, CT has limited sensitivity to detect mild steatosis (<30% liver fat). Radiation exposure is an additional drawback. Although CT can quantitatively measure hepatic steatosis, it is an unfavorable modality to diagnose fatty liver in the clinical setting. A few clinical trials of patients with T2DM applied CT scan to monitor changes in hepatic steatosis [57 58].

Magnetic resonance imaging

To date, MRI showed the most powerful performance for assessing steatosis. MRI-based methods are generally divided into two classes: MRS and MRI-proton density fat fraction (MRI-PDFF). MRS is considered the gold standard for quantification of hepatic triglyceride (fat) content [42 44], as it is sensitive enough to detect trace amounts of liver fat. MRS is more a biochemical-based technique than imaging. It quantifies the signal intensity of proton at frequencies corresponding to water or fat within the voxel-of-interest, and the fat signal fraction is calculated. In a recent meta-analysis with histology as the reference, MRS showed high diagnostic accuracy to detect mild steatosis (histological grade ≥5%) with sensitivity and specificity of 89% and 84%, respectively [59]. However, major limitations of MRS are: high cost; time consumption; need for specialized expertise and devices; and small volume of measurements (usually <3×3×3 cm in size), which may cause sampling errors.

Several MRI-based methods have been developed for measuring liver fat content. MRI-PDFF is a fundamental tissue trait and can be calculated as the (proton signal from magnetic resonance [MR]-visible triglyceride)/(total proton signal including triglyceride and water) [54 60]. Therefore, internal calibration or a reference standard is not needed. The diagnostic accuracy of MRI-PDFF to detect steatosis is comparable to MRS or liver biopsy [45 54 61], while it also allows whole imaging of the liver where fat is measured. This can minimize sampling error, making MRI-PDFF useful for monitoring patients sequentially, such as in NAFLD clinical trials [45 62 63].

Transient elastography

Controlled attenuation parameter (CAP) is a simple quantitative index based on the properties of ultrasonic signals examined by transient liver elastography (Fibroscan; Echosens, Paris, France). Based on the concept that fat attenuates US propagation, it quantifies US attenuation at the center frequency of the Fibroscan M probe (3.5 MHz) or XL probe (2.5 MHz) within approximately 3 cm3 of liver volume [64]. Recent meta-analysis with CAP measurements in patients with various chronic liver diseases including NAFLD (20% of the total population), demonstrated its diagnostic accuracy to detect hepatic steatosis with sensitivity and specificity of 69% and 82%, respectively (area under the receiver operating characteristic curve [AUROC]=0.823) [46]. Optimal cut-off values for defining S1, S2, and S3 were 248, 268, and 280 dB/m, respectively. The authors proposed that individual CAP values should be interpreted after adjustment for presence of diabetes, steatosis etiology (NAFLD), and BMI, as these factors can overrate CAP values [46]. Wong et al. [65] recently established validity criteria for CAP measurement by M probe in clinical practice. Interquartile range (IQR), which can be derived from 10 repeated values of CAP, reflects the fluctuation of CAP measurements. If IQR >40 dB/m, accuracy of CAP to diagnose steatosis substantially declines. Caussy et al. [47] proposed a cut-off value of 288 dB/m for CAP measurement of hepatic steatosis (defined as MRI-PDFF ≥5%), with improved diagnostic accuracy when the IQR was <30 dB/m. The discrepancy in CAP cut-points in the two previous studies may be due to differences in obesity prevalence, NAFLD, and diabetes. To reduce the failure rate of CAP measurements in obese (BMI ≥30 kg/m²) patients, XL probe is recommended [66 67]. In biopsy-proven NAFLD patients, MRI-PDFF was more accurate than CAP in diagnosing all grades of steatosis [48 68]. Notably, CAP showed a non-linear relationship with liver fat content in patients with severe fatty liver, indicating a limitation to discriminate moderate and severe steatosis (grade 2 vs. 3). Lee et al. [69] recently conducted an efficacy study of NAFLD using CAP as a primary endpoint in T2DM patients, to assess its utility in clinical trials.

Compared to MRI-PDFF, TE-based CAP showed relatively lower accuracy to detect steatosis whereas its advantages include cost and accessibility. More research on these modalities, to evaluate and define their distinct roles, are warranted [70].

IMAGING MODALITIES TO ASSESS NASH AND HEPATIC FIBROSIS

To date, no imaging technique can reliably diagnose NASH. In contrast, liver fibrosis can be indirectly quantified by measuring liver stiffness using imaging modalities such as magnetic resonance elastography (MRE) and TE, because fibrotic liver contains a high level of collagen resulting in tissue rigidity.

Magnetic resonance elastography

MRE uses vibration to generate low frequency mechanical waves in liver tissue, visualize the propagating waves using a phase contrast MRI technique, and then transform the wave information into quantitative images reflecting liver stiffness [71]. Contrary to the European NAFLD guidelines, United States guidelines state that MRE is useful to identify advanced fibrosis in patients with NAFLD [40] due to its better performance in discriminating stage 1 and ≥2 fibrosis compared to TE [68]; furthermore, MRE's superiority to detect fibrosis was confirmed in a meta-analysis [49]. Although it is reliable, reproducible, and the most accurate method for estimating hepatic fibrosis, MRE is expensive, not widely available in many clinics, and requires specialized expertise to obtain acceptable images.

Transient elastography

TE (Fibroscan) is a point-of-care imaging technique using US in which propagation velocity directly reflects tissue elasticity to 1 cm wide and 4 cm long [72]. This can quickly generate a surrogate marker of liver fibrosis stage called liver stiffness measurement (LSM). Results are described as the median values of 10 validated measurements, ranging from 2.5 to 75.0 kilopascals (kPa), with healthy liver values <5.5 kPa [73]. Importantly, validity criteria of LSM by TE include a success rate (ratio of valid measurements to total measurements) >60% and an IQR/median LSM ratio of <0.3 [74]. TE has been intensively studied in patients with viral hepatitis; however, its diagnostic accuracy for hepatic fibrosis was recently validated in NAFLD patients [50 75]. Notably, LSM was more correlated with fibrosis stage in individuals with severe fibrosis (F3) and cirrhosis (F4) [75 76]. TE has higher negative predictive values for excluding advanced fibrosis than positive predictive values for detection [75], indicating that additional surrogate markers for fibrosis can enhance the ability to diagnose advanced fibrosis or cirrhosis. A major weakness of TE is a high failure risk in obese patients [77] and low accuracy to detect fibrosis in high BMI patients [75]. As T2DM patients tend to be obese, this issue should be carefully considered before utilizing TE. In such cases, XL-probe may provide more reliable results for morbidly obese patients [78]. Due to its accessibility, low cost, and moderate accuracy, TE is recommended by both United States and European NAFLD guidelines as an acceptable non-invasive method to identify patients at low risk of advanced fibrosis/cirrhosis [40 42].

BIOMARKER-BASED PREDICTION MODELS TO ASSESS STEATOSIS, NASH, AND HEPATIC FIBROSIS

Besides imaging modalities, several noninvasive biomarker models have been developed to predict NASH and fibrosis. As NAFLD patients with diabetes are at high risk for NASH and fibrosis, which are significantly associated with morbidity and mortality, evaluation of these conditions is essential for clinical management [42]. Models incorporating both clinical and laboratory parameters, which are directly or indirectly linked to liver status, provide enhanced diagnostic accuracy to identify high risk individuals [79].

Hepatic steatosis

Many noninvasive prediction models have been proposed to detect hepatic steatosis in NAFLD cohorts (Table 3) [80 81 82 83 84 85 86 87]. The majority of models are derived from datasets with fatty liver defined by US. European NAFLD guidelines state that fatty liver index (FLI), SteatoTest (BioPredictive, Paris, France), and NAFLD liver fat score are well-validated models to detect steatosis in the general population [42]. FLI, NAFLD liver fat score, hepatic steatosis index (HSI), and comprehensive/simple NAFLD scores (CNS/SNS) were externally validated in the Korean population. Depending on population characteristics, cut-off values of these models might be adjusted to improve sensitivity and specificity [80]. Epidemiologic studies with no imaging information can apply these models to calculate an operational definition for hepatic steatosis [88], but prudent interpretation/application of multiple models is needed. However, these biomarker-based indices do not add much diagnostic information for clinicians who routinely perform imaging studies such as US for patients with suspected NAFLD.

NASH

Currently there are no well-established prediction models or biomarkers to distinguish NASH from steatosis, despite intensive efforts [42]. Circulating levels of cytokeratin-18 (CK-18) fragments, which are released from apoptotic or dead cells, have been extensively investigated as a novel biomarker [89]; however, its clinical utility remains unknown due to low reproducibility and measurement issues [90]. Other panels combined with novel biomarkers, such as NASH test (BioPredictive) [91], NASH diagnostics [92], and OxNASH score [93] have been introduced. Further research is required to validate their accuracy and practical utility.

Hepatic fibrosis

Severity of hepatic fibrosis is the most powerful determinant of long-term outcomes, including mortality [94 95]; thus, noninvasive assessment of fibrosis is essential to manage patients with NAFLD. Beyond imaging modalities to estimate hepatic fibrosis, several prediction scores have been developed and validated to identify or exclude advanced fibrosis. Focusing on reliable blood-based predictive models in the NAFLD guidelines, equations, cut-points for advanced fibrosis (F3), information about the original development cohort, and external validation in individuals with NAFLD are summarized in Table 4 [96 97 98 99 100 101 102 103 104]. This review does not compare diagnostic performance of these models due to limited space.

Contrary to steatosis or NASH scores, fibrosis prediction models in clinical practice are recommended in the recent NAFLD guidelines [40 42] because some models have achieved acceptable accuracy to detect significant fibrosis and have been widely validated in NAFLD patients. The NAFLD fibrosis score (NFS) [96] and fibrosis-4 (FIB-4) index [97] are currently the most studied decision-making systems and are clinically endorsed by both European and United States NAFLD guide lines. The National Institute for Health and Care Excellence (NICE, London, United Kingdom) recommended use of the Enhanced Liver Fibrosis (ELF) panel, a commercial diagnostic kit using fibrosis-related biomarkers, for NAFLD management. These blood-based fibrosis prediction models perform better when excluding advanced fibrosis versus diagnosing it, due to higher negative predictive values [105]. Therefore, combining results from both imaging modalities and biomarker-based scores may be a better approach to identify ambiguous patients at risk for advanced fibrosis or who need liver biopsy.

CONCLUSIONS

Compared to the general population, NAFLD is widely prevalent in patients with T2DM, and incidence of both metabolic diseases is steadily increasing worldwide. Accumulating evidence indicates that T2DM is considered an emerging risk factor for NASH and/or fibrosis and that NAFLD may worsen diabetes-related health outcomes, such as vascular complications, and mortality. Extensive assessment of NAFLD severity and of cardiometabolic risk profiles is highly recommended for management of patients with T2DM. Although many imaging modalities and biomarker-based prediction models have been developed to evaluate NAFLD disease status, more investigation is required before their application in routine clinical care.

ACKNOWLEDGMENTS

Editorial assistance was provided by Caron Modeas.

Notes

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

References

1. International Diabetes Federation: IDF Diabetes Atlas: Key Messages. cited 2019 Feb 8. Available from: http://diabetesatlas.org/key-messages.html.

2. Korean Diabetes Association: Diabetes Fact Sheet in Korea 2018. cited 2019 Feb 8. Available from: http://www.diabetes.or.kr/pro/news/admin.php?category=A&code=admin&number=1615&mode=view.

3. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017; 14:32–42. PMID: 27729660.

4. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66:1138–1153. PMID: 28314735.

5. Younossi Z, Tacke F, Arrese M, Sharma BC, Mostafa I, Bugianesi E, Wong VW, Yilmaz Y, George J, Fan J, Vos MB. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology. 2018; 9. 04. DOI: 10.1002/hep.30251. [Epub].

6. Younossi ZM. Non-alcoholic fatty liver disease: a global public health perspective. J Hepatol. 2018; 11. 09. DOI: 10.1016/j.jhep.2018.10.033. [Epub].

7. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006; 21(1 Pt 1):138–143. PMID: 16706825.

8. Jeong EH, Jun DW, Cho YK, Choe YG, Ryu S, Lee SM, Jang EC. Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol. 2013; 19:266–272. PMID: 24133664.

9. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015; 47:181–190. PMID: 25739820.

10. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40:1387–1395. PMID: 15565570.

11. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015; 100:2231–2238. PMID: 25885947.

12. Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2014; 5:170–175.

13. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T. JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47:586–595. PMID: 22328022.

14. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10:330–344. PMID: 23507799.

15. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016; 31:936–944. PMID: 26667191.

16. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults. Diabet Med. 2008; 25:476–481. PMID: 18346164.

17. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011; 96:1093–1097. PMID: 21252243.

18. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013; 98:3637–3643. PMID: 23873989.

19. Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care. 2015; 38:1673–1679. PMID: 26156527.

20. Bae JC, Han JM, Cho JH, Kwon H, Park SE, Park CY, Lee WY, Oh KW, Kwon S, Park SW, Rhee EJ. The persistence of fatty liver has a differential impact on the development of diabetes: the Kangbuk Samsung Health Study. Diabetes Res Clin Pract. 2018; 135:1–6. PMID: 29111276.

21. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012; 35:717–722. PMID: 22338098.

22. Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care. 2011; 34:727–729. PMID: 21278140.

23. Bae JC, Kim SK, Han JM, Kwon S, Lee DY, Kim J, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome. Diabetes Res Clin Pract. 2017; 129:136–143. PMID: 28527304.

24. Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, Oh KW, Park SW, Lee WY. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res. 2013; 44:115–120. PMID: 23398788.

25. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol. 2013; 108:1861–1868. PMID: 24100261.

26. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012; 33:1190–1200. PMID: 22408036.

27. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44:865–873. PMID: 17006923.

28. Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, Kong AP, Wong VW. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016; 65:1359–1368. PMID: 25873639.

29. Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, Leebeek FW, Hofman A, Stricker BH, Castera L, Janssen HL. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016; 63:138–147. PMID: 26171685.

30. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015; 62:1148–1155. PMID: 25477264.

31. Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai RK, Dasarathy S, McCullough AJ. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2014; 3:141–145. PMID: 26675585.

32. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7:1224–1229. PMID: 19559819.

33. Han E, Lee YH. Non-alcoholic fatty liver disease: the emerging burden in cardiometabolic and renal diseases. Diabetes Metab J. 2017; 41:430–437. PMID: 29199410.

34. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007; 30:2119–2121. PMID: 17519430.

35. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008; 51:444–450. PMID: 18058083.

36. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010; 105:1567–1573. PMID: 20145609.

37. Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of cardiovascular disease in type 1 diabetic patients with non-alcoholic fatty liver disease. J Endocrinol Invest. 2012; 35:535–540. PMID: 21795844.

38. Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, Pancheri S, Trombetta M, Zoppini G, Chonchol M, Byrne CD, Bonora E. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014; 37:1729–1736. PMID: 24696459.

39. Byrne CD, Patel J, Scorletti E, Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ. 2018; 362:k2734. PMID: 30002017.

40. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67:328–357. PMID: 28714183.

41. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128:1898–1906. PMID: 15940625.

42. European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64:1388–1402. PMID: 27062661.

43. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009; 51:433–445. PMID: 19604596.

44. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288:E462–E468. PMID: 15339742.

45. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016; 65:1006–1016. PMID: 27312947.

46. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66:1022–1030. PMID: 28039099.

47. Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, Ajmera V, Bettencourt R, Collier S, Hooker J, Sy E, Rizo E, Richards L, Sirlin CB, Loomba R. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018; 67:1348–1359. PMID: 29108123.

48. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Alquiraish MH, Valasek MA, Rizo E, Richards L, Brenner D, Sirlin CB, Loomba R. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017; 152:598–607. PMID: 27911262.

49. Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, Le MD, Hooker J, Tu X, Bettencourt R, Yin M, Sirlin CB, Ehman RL, Nakajima A, Loomba R. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2018; 6. 14. DOI: 10.1016/j.cgh.2018.05.059. [Epub].

50. Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2016; 111:677–684. PMID: 26977758.

51. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123:745–750. PMID: 12198701.

52. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54:1082–1090. PMID: 21618575.

53. Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 2002; 8:1114–1122. PMID: 12474149.

54. Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, Hooker JC, Szeverenyi N, Sirlin CB. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018; 91:20170959. PMID: 29722568.

55. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology. 1980; 137:727–729. PMID: 6934563.

56. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011; 21:87–97. PMID: 20680289.

57. Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, Akiyama Y, Morimoto Y, Noda M, Shimada A. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017; 40:1364–1372. PMID: 28751548.

58. Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, Kawai H, Ohashi N, Mori A. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. 2018; 20:438–442. PMID: 28719078.

59. Zheng D, Guo Z, Schroder PM, Zheng Z, Lu Y, Gu J, He X. Accuracy of MR imaging and MR spectroscopy for detection and quantification of hepatic steatosis in living liver donors: a meta-analysis. Radiology. 2017; 282:92–102. PMID: 27479639.

60. Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, Hassanein T, Patton HM, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology. 2009; 251:67–76. PMID: 19221054.

61. Yokoo T, Serai SD, Pirasteh A, Bashir MR, Hamilton G, Hernando D, Hu HH, Hetterich H, Kuhn JP, Kukuk GM, Loomba R, Middleton MS, Obuchowski NA, Song JS, Tang A, Wu X, Reeder SB, Sirlin CB. RSNA-QIBA PDFF Biomarker Committee. Linearity, bias, and precision of hepatic proton density fat fraction measurements by using MR imaging: a meta-analysis. Radiology. 2018; 286:486–498. PMID: 28892458.

62. Loomba R. Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. J Hepatol. 2018; 68:296–304. PMID: 29203392.

63. Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016; 65:369–376. PMID: 27151177.

64. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, Miette V. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010; 36:1825–1835. PMID: 20870345.

65. Wong VW, Petta S, Hiriart JB, Camma C, Wong GL, Marra F, Vergniol J, Chan AW, Tuttolomondo A, Merrouche W, Chan HL, Le Bail B, Arena U, Craxi A, de Ledinghen V. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol. 2017; 67:577–584. PMID: 28506907.

66. de Ledinghen V, Hiriart JB, Vergniol J, Merrouche W, Bedossa P, Paradis V. Controlled attenuation parameter (CAP) with the XL probe of the Fibroscan(R): a comparative study with the M probe and liver biopsy. Dig Dis Sci. 2017; 62:2569–2577. PMID: 28577247.

67. Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, Choi PC, Merrouche W, Chu SH, Pesque S, Chan HL, de Ledinghen V. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012; 107:1862–1871. PMID: 23032979.

68. Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, Yoneda M, Taguri M, Hyogo H, Sumida Y, Ono M, Eguchi Y, Inoue T, Yamanaka T, Wada K, Saito S, Nakajima A. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016; 150:626–637. PMID: 26677985.

69. Lee YH, Kim JH, Kim SR, Jin HY, Rhee EJ, Cho YM, Lee BW. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci. 2017; 32:60–69. PMID: 27914133.

70. Karlas T, Petroff D, Wiegand J. Collaboration, not competition: the role of magnetic resonance, transient elastography, and liver biopsy in the diagnosis of nonalcoholic fatty liver disease. Gastroenterology. 2017; 152:479–481. PMID: 28038929.

71. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013; 37:544–555. PMID: 23423795.

72. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29:1705–1713. PMID: 14698338.

73. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10:666–675. PMID: 24061203.

74. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008; 48:835–847. PMID: 18334275.

75. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, de Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010; 51:454–462. PMID: 20101745.

76. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008; 134:960–974. PMID: 18395077.

77. Foucher J, Castera L, Bernard PH, Adhoute X, Laharie D, Bertet J, Couzigou P, de Ledinghen V. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006; 18:411–412. PMID: 16538113.

78. de Ledinghen V, Wong VW, Vergniol J, Wong GL, Foucher J, Chu SH, Le Bail B, Choi PC, Chermak F, Yiu KK, Merrouche W, Chan HL. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol. 2012; 56:833–839. PMID: 22173167.

79. Lee YH, Bang H, Kim DJ. How to establish clinical prediction models. Endocrinol Metab (Seoul). 2016; 31:38–44. PMID: 26996421.

80. Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, Cha BS, Lee HC, Balkau B, Lee WY, Kim DJ. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One. 2014; 9:e107584. PMID: 25216184.

81. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. PMID: 17081293.

82. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005; 4:10. PMID: 16375767.

83. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstrale M, Groop L, Orho-Melander M, Yki-Jarvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137:865–872. PMID: 19524579.

84. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010; 42:503–508. PMID: 19766548.

85. Wang J, Xu C, Xun Y, Lu Z, Shi J, Yu C, Li Y. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep. 2015; 5:16494. PMID: 26568423.

86. Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann U, Muntner P, Fox CS. Development and validation of the Framingham Steatosis Index to identify persons with hepatic steatosis. Clin Gastroenterol Hepatol. 2016; 14:1172–1180. PMID: 27046482.

87. Xia MF, Yki-Jarvinen H, Bian H, Lin HD, Yan HM, Chang XX, Zhou Y, Gao X. Influence of ethnicity on the accuracy of non-invasive scores predicting non-alcoholic fatty liver disease. PLoS One. 2016; 11:e0160526. PMID: 27579785.

88. Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, Kang ES, Han KH, Lee HC, Cha BS. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015; 63:486–493. PMID: 25772036.

89. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009; 50:1072–1078. PMID: 19585618.

90. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018; 68:349–360. PMID: 29222917.

91. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V. LIDO Study Group. CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6:34. PMID: 17096854.

92. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008; 18:1430–1437. PMID: 18500507.

93. Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R, McIntyre TM, Feldstein AE, Hazen SL. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci. 2014; 59:1617–1624. PMID: 24464211.

94. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017; 65:1557–1565. PMID: 28130788.

95. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015; 61:1547–1554. PMID: 25125077.

96. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45:846–854. PMID: 17393509.

97. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43:1317–1325. PMID: 16729309.

98. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008; 47:455–460. PMID: 18038452.

99. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. 2009; 136:160–167. PMID: 18992746.

100. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357:1069–1075. PMID: 11297957.

101. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38:518–526. PMID: 12883497.

102. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57:1441–1447. PMID: 18390575.

103. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005; 51:1867–1873. PMID: 16055434.

104. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J, Ducluzeaux PH, Lunel F. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009; 50:165–173. PMID: 18977552.

105. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018; 68:305–315. PMID: 29154965.

Table 1

Secondary causes of hepatic fat accumulation

Categories	Description
Alcohol	Intake, weekly: >140 g or 14 standard drinks (women), >210 g or 21 standard drinks (men)
Viral hepatitis	Serological evidence for hepatitis B or hepatitis C virus infection
Steatogenic drugs	Exposure history of valproic acid, tamoxifen, aromatase inhibitors, corticosteroids, tetracycline, amiodarone, methotrexate, mipomersen, lomitapide, etc.
Autoimmune disorder	Autoimmune hepatitis, celiac disease
Hereditary liver diseases	Hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, lipodystrophy
Others	Hypobetalipoproteinaemia, surgically altered bowel anatomy, pancreatoduodenal resection, etc.

Table 2

Summary of currently used imaging devices for quantification of hepatic steatosis and fibrosis

Device	Detection criteria	Accuracy reproducibility quantification	Hepatic volume of assessment	Time accessibility	Cost	Specific comments
Hepatic steatosis
US	Specific sonographic findings [51]	+	+++	+ (bedside)	+	Cannot detect mild steatosis, Observer dependency
CT	liver HU <40 or liver HU−spleen HU <−10 [43]	++	+++	++	++	Radiation hazard
						Diverse criteria for definition (liver/spleen ratio of HU, etc.)
						Low sensitivity in mild steatosis
MRI-PDFF	≥5.6% liver fat [42 44]	+++	+++	+++	+++	Optimal for clinical trials
MRS		+++	+	+++	+++	Gold standard Sampling errors Require expertise/device
CAP by TE	CAP ≥248 dB/m [46] or ≥288 dB/m [47]	++	+	+ (bedside)	+	Not linear in higher liver fat content
						Results are affected by BMI, diabetes, etiology
						XL probe for the obese
Hepatic fibrosis
MRE	Advanced fibrosis (F3) threshold >2.4–5.55 kPa [45]	+++	+++	+++	+++	Diverse cut-points by types of modality (2D, 3D, etc.)
						Most accurate but expensive
						Failure risk in iron overload condition
LSM by TE	Diverse cut-points (7.3–9.9 kPa) for advanced fibrosis (F3) [48 49 50]	++	+	+ (bedside)	+	Affected by BMI (failure risk)
						XL probe for the obese
						TE can measure CAP and LSM simultaneously

US, ultrasonography; CT, computed tomography; HU, Hounsfield unit; MRI-PDFF, magnetic resonance imaging proton density fat fraction; MRS, magnetic resonance spectroscopy; CAP, controlled attenuation parameter; TE, transient elastography; BMI, body mass index; MRE, magnetic resonance elastography; kPa, kilopascals; LSM, liver stiffness measurement; 2D, two dimensional; 3D, three dimensional; CAP, controlled attenuation parameter.

Table 3

Summary of biomarker-based prediction models to assess hepatic steatosis

Indices	Equations	Cut-points	Development cohort	External validation
FLI (2006) [81]	=1/[1+exp (−Y)]×100, Y=0.953×log_e (TG, mg/dL)+0.139×BMI+0.718×log_e (GGT, U/L)+0.053×WC− 15.745	≥60, <30	NAFLD by US (Italy)	Yes (validated in Korean)
SteatoTest (2005) [82]	α2-Macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, FPG, TG, cholesterol, ALT, age, sex, BMI	NA	NAFLD by biopsy (France)	Yes
NAFLD liver fat score (2009) [83]	=−2.89+1.18×MetS+0.45×diabetes (yes=2/no=0)+0.15×(fSinsulin, μU/L)+ 0.04×AST+0.94×AST/ALT	>−0.64	NAFLD by MRS (Finland)	Yes (validated in Korean)
HIS (2010) [84]	=8×ALT/AST+BMI (+2, if diabetes; +2, if female)	≥36, <30	NAFLD by US (Korean)	Yes (validated in Korean)
CNS (2014) [80]	=1/[1+exp (−Y)]×100	≥40	NAFLD by US (Korean)	Yes (validated in Korean)
	Y (male)=0.016×age+0.182×BMI+0.089×WC+0.391×alcohol+0.124×exercise (yes=0/no=1)+0.018×FPG (mg/dL)+0.773×log_e (TG, mg/dL)−0.014×HDL-C (mg/dL)+0.145×uric acid (mg/dL)−0.674×log_e (AST)+1.632×log_e (ALT)−21.695
	Y (female)=0.320×BMI+0.044×WC+0.533×diabetes+0.016×FPG+0.951×log_e (TG)−0.015×HDL-C+0.199×uric acid−0.645×log_e (AST)+1.302×log_e (ALT)+0.255×menopause−19.741
SNS (2014) [80]	=Points, Age ≥35=1	≥8	NAFLD by US (Korean)	Yes (validated in Korean)
	WC (male)=80–89/90–99/≥100=2/3/4
	WC (female)=75–84/85–94/≥95=1/2/3
	BMI (male)=23–24/25–26/≥27=1/2/3
	BMI (female)=23–24/25–26/≥27=2/3/4
	Diabetes=2
	Dyslipidemia=2
	No regular exercise=1
	Alcohol=1 for male
	Menopause=1 for female
ZJU index (2015) [85]	=BMI+FPG (mmol/L)+TG (mmol/L)+3×ALT/AST (+2, if female)	> 38, <32	NAFLD by US (China)	Yes
FSI (2016) [86]	=−7.981+0.011×age (years)−0.146×sex (female=1, male=0)+0.173× BMI+0.007×TG (mg/dL)+0.593×hypertension+0.789×diabetes+1.1×ALT/AST ratio ≥1.33 (yes=1, no=0)	≥23	NAFLD by CT (USA)	Yes
Chinese NAFLD score (2016) [87]	=−4.632+0.303×MetS+0.157×T2DM (yes =2, no=0)+0.078×fSinsulin (μU/L)+0.168×BMI−0.879×AST/ALT	>−0.79	NAFLD by US (China)	Yes

FLA, fatty liver index; TG, triglyceride; BMI, body mass index; GGT, γ-glutamyltransferase; WC, waist circumference; NAFLD, nonalcoholic fatty liver disease; US, ultrasonography; FPG, fasting plasma glucose; ALT, alanine aminotransferase; NA, not available; MetS, metabolic syndrome; fSinsulin, fasting serum insulin; AST, aspartate aminotransferase; MRS, magnetic resonance spectroscopy; HSI, hepatic steatosis index; CNS, comprehensive NAFLD score; HDL-C, high density lipoprotein cholesterol; SNS, simple NAFLD score; ZJU, Zhejiang University; FSI, Framingham Steatosis Index; CT, computed tomography; T2DM, type 2 diabetes mellitus.

Table 4

Summary of biomarker-based prediction models to assess hepatic fibrosis

Indices	Equations	Cut-points for advanced fibrosis (F3)	Development cohort	External validation in NAFLD
NFS (2007) [96]	=−1.675+0.037×age (years)+0.094×BMI (kg/m²)+1.13×IFG/diabetes (yes=1, no=0)+0.99×AST/ALT ratio−0.013×platelet (×109/L)−0.66× albumin (g/dL)	>0.676, <-1.455	NAFLD by biopsy (Caucasian 90%)	Yes (validated in Korean)
FIB-4 (2006) [97]	=age (years)×AST (U/L)/[platelet (109/L)×(ALT [U/L])1/2]	>2.67 or 3.25	HIV/HCV by biopsy (International, Caucasian 77%)	Yes (validated in Korean)
ELF test (2008) [98 99]	ELF=-7.412+0.681×log_e (hyaluronic acid)+0.775×log_e (procollagen III N-terminal peptide)+0.494×log_e (tissue inhibitor of metalloproteinase 1)+10	≥10.51	NAFLD by biopsy (Caucasian)	Yes (validated in viral liver diseases, Korean)
ELF test (2008) [98 99]	ELF+simple markers panel=−20.870+5.506×ELF 4.513×diabetes⁄IFG−3.14 4×AST⁄ALT−0.058×BMI−0.026×platelet (109/L) 0.639×albumin (g/dL)	≥10.51	NAFLD by biopsy (Caucasian)	Yes (validated in viral liver diseases, Korean)
FibroTest (2001) [100]	Age, sex, total bilirubin, GGT, apolipoprotein A1, haptoglobin, and α2-macroglobulin	≥0.30 or 0.60	HCV by biopsy (France)	Yes (validated in viral liver diseases, Korean)
APRI (2003) [101]	=AST (IU/L)/AST upper limit of normal (IU/L)/platelet (109/L)	>1.5, <0.5	HCV by biopsy (USA)	Yes (validated in viral liver diseases, Korean)
BARD score (2008) [102]	AST/ALT ratio ≥0.8=2 points	≥2	NAFLD by biopsy (USA)	Yes (validated in Korean)
	BMI ≥28=1 point
	Presence of diabetes=1 point
Hepascore (2005) [103]	=Y/(1+Y)	≥0.5	HCV by biopsy (Australia)	No
Hepascore (2005) [103]	Y=exp (−4.185818−0.0249×age+0.7464×sex+1.0039×α2-macroglobulin+0.0302×hyaluronic acid+0.0691×bilirubin−0.0012×GGT)	≥0.5	HCV by biopsy (Australia)	No
FibroMeter NAFLD (2009) [104]	=0.4184×FPG (mmol/L)+0.0701×AST (UI/L)+0.0008×ferritin (μg/L)−0.0102×platelet (G/L)−0.0260×ALT (UI/L)+0.0459×body weight (kg)+0.0842×age (year)+11.6226	>0.490: significant fibrosis (F2)	NAFLD by biopsy (France)	No

NAFLD, nonalcoholic fatty liver disease; NFS, NAFLD fibrosis score; BMI, body mass index; IFG, impaired fasting glucose; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FIB-4, fibrosis-4; HIV, human immunodeficiency virus; HCV, hepatitis C virus; ELF, Enhanced Liver Fibrosis; GGT, γ-glutamyltransferase; APRI, AST to platelet ratio index; FPG, fasting plasma glucose.

TOOLS

Similar articles